Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A small pilot study found that oxaloacetate — a naturally occurring compound — significantly improved cognitive function in breast cancer survivors struggling with post-treatment "chemo brain." All 16 women who completed the 8-week regimen showed meaningful improvements in cognition, fatigue, and physical functioning. A randomized, placebo-controlled phase 2 trial has now received FDA approval and is expected to launch soon.
For the up to 25% of breast cancer survivors who experience persistent cognitive difficulties long after treatment ends, there have been virtually no effective pharmacologic options — until now. A small pilot study out of UCLA tested anhydrous enol-oxaloacetate (OAA), a naturally occurring metabolic compound, in 18 breast cancer survivors with moderate-to-severe cancer-related cognitive impairment (CRCI). All 16 women who completed the 8-week course of 500 mg twice daily reported dramatic improvements in perceived cognition, fatigue, and physical functioning.
The working theory is that OAA helps restore mitochondrial function and glutamate signaling — both of which can be disrupted by cancer treatments like chemotherapy and endocrine therapy — potentially reversing some of the accelerated metabolic aging associated with cancer. Preclinical mouse model data supported these findings. The FDA has since approved a randomized, placebo-controlled phase 2 trial to confirm the results.
By the Numbers:
Why it matters: CRCI is one of the most underaddressed consequences of cancer treatment, often leaving survivors unable to return to work or daily life. If the upcoming placebo-controlled trial confirms these results, OAA could become the first targeted intervention for chemo brain — a significant unmet need across multiple cancer types.
